Erik Baubeta Fridh

Erik Baubeta Fridh


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
EFErik Baubeta Fridh
Erik Baubeta Fridh
MAM. Andersson
M. Andersson
MTM. Thuresson
M. Thuresson
BSB. Sigvant
B. Sigvant
BKB. Kragsterman
B. Kragsterman
JNJoakim Nordanstig
Joakim Nordanstig

1 November 2018 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Closed access
EFErik Baubeta Fridh
Erik Baubeta Fridh
MAManne Andersson
Manne Andersson
MTMarcus Thuresson
Marcus Thuresson
BSBirgitta Sigvant
Birgitta Sigvant
BKBjörn Kragsterman
Björn Kragsterman
MFMårten Falkenberg
Mårten Falkenberg

22 September 2022 in JHEP Reports
Verified
Journal Article
Open access
AGAristeidis Grigoriadis
Aristeidis Grigoriadis
KRKristina Imeen Ringe
Kristina Imeen Ringe
JBJohan Bengtsson
Johan Bengtsson
EFErik Baubeta Fridh
Erik Baubeta Fridh
CFCecilia Forsman
Cecilia Forsman
ABAnnika Bergquist
Annika Bergquist
Magnetic resonance cholangiopancreatography (MRCP) is used for the diagnosis and follow-up of individuals with primary sclerosing cholangitis (PSC). The aim of our study is to develop an MRCP-score based on cholangiographic findings previously associated with outcomes and assess its reproducibility and prognostic value in PSC. The score (DiStrict score) was developed based on the extent and severity of cholangiographic changes of intrahepatic and extrahepatic bile ducts (range 0–8) on 3D-MRCP. In this retrospective, multicentre study, three pairs of radiologists with different levels of expertise from three tertiary centres applied the score independently. MRCP examinations of 220 consecutive individuals with PSC from a prospectively collected PSC-cohort, with median follow-up of 7.4 years, were reviewed. Inter-reader and intrareader agreements were assessed via intraclass correlation coefficient (ICC). After consensus, the prognostic value of the score was assessed using Cox-regression and outcome-free survival rates were assessed via Kaplan-Meier estimates. Harrell's C-statistic was calculated. Forty patients developed outcomes (liver transplantation or liver-related death). Inter-reader agreement between experienced radiologists was good (ICC 0.82; 95% CI 0.74–0.87, and ICC 0.81; 95% CI 0.70–0.87, respectively) and better than the agreement for the pair of experienced/less-experienced radiologists (ICC 0.48; 95% CI 0.05–0.72). Agreement between radiologists from the three centres was good (ICC 0.76; 95% CI 0.57–0.89). Intrareader agreement was good to excellent (ICC 0.85–0.93). Harrell's C was 0.78. Patients with a DiStrict score of 5–8 had 8.2-fold higher risk (hazard ratio 8.2; 95% CI 2.97–22.65) of developing outcomes, and significantly worse survival (p <0.001), compared to those with a DiStrict score of 1–4. The novel DiStrict score is reproducible and strongly associated with outcomes, indicating its prognostic value for individuals with PSC in clinical practice. The diagnosis of primary sclerosing cholangitis (PSC) is based on magnetic resonance cholangiopancreatography (MRCP). However, the role of MRCP in the prognostication of PSC is still unclear. We developed a novel, simple, and reproducible risk-score, based on MRCP findings, that showed a strong association with prognosis in individuals with PSC (DiStrict score). This score can be easily used in clinical practice and thus has the potential to be useful in clinical trials and in patient counselling and management.

10 August 2023 in BJU International
Verified
Journal Article
Open access
MAMax Alterbeck
Max Alterbeck
ETErik Thimansson
Erik Thimansson
JBJohan Bengtsson
Johan Bengtsson
EFErik Baubeta Fridh
Erik Baubeta Fridh
SZSophia Zackrisson
Sophia Zackrisson
ABAnders Bjartell
Anders Bjartell
Objective: To determine the feasibility of a digitally automated population‐based programme for organised prostate cancer testing (OPT) in Southern Sweden. Patients and Methods: A pilot project for a regional OPT was conducted between September 2020 and February 2021, inviting 999 randomly selected men aged 50, 56, or 62 years. Risk stratification was based on prostate‐specific antigen (PSA) level, PSA density (PSAD), and bi‐parametric prostate magnetic resonance imaging (MRI). Men with a PSA level of 3–99 ng/mL had an MRI, and men with elevated PSA level (≥3 ng/mL) had a urological check‐up, including a digital rectal examination and transrectal ultrasonography (TRUS). Indications for targeted and/or systematic transrectal prostate biopsies were suspicious lesions on MRI (Prostate Imaging‐Reporting and Data System [PI‐RADS] 4–5) and/or PSAD > 0.15 ng/mL/mL. Additional indications for prostate biopsies were palpable tumours, PSA ratio < 0.1, or cancer suspicion on TRUS. Patient selection, mail correspondence, data collection, and algorithm processing were performed by an automated digital management system. Feasibility is reported descriptively. Results: A total of 418 men had a PSA test (42%), with increasing participation rates by age (50 years, 38%; 56 years, 44%; and 62 years, 45%). Among these, 35 men (8%) had elevated PSA levels (≥3 ng/mL: one of 139, aged 50 years; 10/143, aged 56 years; and 24/146, aged 62 years). On MRI, 16 men (48%) had a negative scan (PI‐RADS < 3), seven men (21%) had PI‐RADS 3, nine men (27%) had PI‐RADS 4, and one man (3%) had PI‐RADS 5. All men with PI‐RADS 4 or 5 underwent prostate biopsies, as well as two men with PI‐RADS 3 due to PSAD > 0.15 ng/mL/mL or a suspicious finding on TRUS. Prostate cancer was diagnosed in 10 men. Six men underwent active treatment, whereas four men were assigned to active surveillance. Conclusion: Our OPT model is feasible from an operational point of view, but due to the limited scale of this study no conclusions can be made regarding the efficacy of the diagnostic model or outcome.

12 March 2024 in Journal of Applied Clinical Medical Physics
Verified
Journal Article
Open access
EFErik Baubeta Fridh
Erik Baubeta Fridh
EGEva Laurin Gadsböll
Eva Laurin Gadsböll
LWLeon Will
Leon Will
FHFredrik Holmquist
Fredrik Holmquist
MAMarie‐Louise Aurumskjöld
Marie‐Louise Aurumskjöld
Purpose: This study aimed to elucidate whether gadolinium contrast in clinically relevant doses can be used with photon‐counting computed tomography (PCCT) as an alternative contrast agent in clinical applications.Material/methods: A CTDI phantom with 3D printed rods filled with different concentrations of gadolinium and iodine contrast was scanned in a PCCT and an energy‐integrated computed tomography (EICT). Attenuation values at different monoenergetic steps were extracted for each contrast concentration.Results: For PCCT, gadolinium reached an attenuation >100 HU (103 HU) at 40 keV with a concentration 5 mmol/L whereas the same level was reached at 50 keV (118 HU) for 10 mmol/L and 90 keV (114 HU) for 25 mmol/L. For iodine, the same level of attenuation was reached at 100 keV (106 HU) with a concentration 8.75 mg I/mL.For EICT the lowest gadolinium contrast concentration needed to reach >100 HU (108 HU) was 10 mmol/L at 50 keV. For 25 mmol/L 100 HU was reached at 100 keV. For iodine contrast 108 HU was reached at 110 keV for 8.75 mg I/mL.Conclusion: No K‐edge potential or difference in attenuation curves between iodine and gadolinium contrast is detected on the first clinical available PCCT. Clinically relevant attenuation levels were barely achieved in this setting with gadolinium concentrations approved for human use. The results of this study suggest that, given current scanning technology, gadolinium is not a clinically useful contrast agent for computed tomography because no K‐edge was detected.

31 October 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
EFErik Baubeta Fridh
Erik Baubeta Fridh
KLKarin Ludwigs
Karin Ludwigs
ASAngelica Svalkvist
Angelica Svalkvist
MAManne Andersson
Manne Andersson
JNJoakim Nordanstig
Joakim Nordanstig
ÅJÅse A. Johnsson
Åse A. Johnsson
This paper aimed to study the agreement and repeatability, both intra- and interobserver, of infrapopliteal lesion assessment with magnetic resonance angiography (MRA), using the TransAtlantic Inter-Society Consensus (TASC) II criteria, with perioperative digital subtraction angiography (DSA) as a reference. Sixty-eight patients with an MRA preceding an endovascular infrapopliteal revascularization were included. Preoperative MRAs and perioperative DSAs were evaluated in random order by three independent observers using the TASC II classification. The results were analyzed using visual grading characteristics (VGC) analysis and Krippendorff’s α. No systematic difference was found between modalities: area under the VGC curve (AUCVGC) = 0.48 (p = 0.58) or intraobserver; AUCVGC for Observer 1 and 2 respectively, 0.49 (p = 0.85) and 0.53 (p = 0.52) for MRA compared with 0.54 (p = 0.30) and 0.49 (p = 0.81) for DSA. Interobserver differences were seen: AUCVGC of 0.63 (p < 0.01) for DSA and 0.80 (p < 0.01) for MRA. These results were confirmed using Krippendorff’s α for the three observers showing 0.13 (95% confidence interval (CI) −0.07–0.31) for MRA and 0.39 (95% CI 0.23–0.53) for DSA. Poor interobserver agreement was also found in the choice of a target vessel on preoperative MRA: Krippendorff’s α = 0.19 (95% CI 0.01‒0.36). In conclusion, infrapopliteal lesions can be reliably determined on preoperative MRA, but interobserver variability regarding the choice of a target vessel is a major concern that appears to affect the overall TASC II grade.